Tigecycline

Generic Name
Tigecycline
Brand Names
Tygacil, Tigecycline Accord
Drug Type
Small Molecule
Chemical Formula
C29H39N5O8
CAS Number
220620-09-7
Unique Ingredient Identifier
70JE2N95KR
Background

Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.

Indication

For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, ...

Associated Conditions
Bacterial Infections, Community Acquired Pneumonia (CAP), Complicated Intra-Abdominal Infections (cIAIs), Complicated Skin and Skin Structure Infection
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections

First Posted Date
2008-07-22
Last Posted Date
2014-07-14
Lead Sponsor
Melinta Therapeutics, Inc.
Target Recruit Count
150
Registration Number
NCT00719810
Locations
🇺🇸

Riverside Methodist Hospital, Columbus, Ohio, United States

🇺🇸

Physician Alliance Research Center, Anaheim, California, United States

🇺🇸

Tri City Medical Center, Oceanside, California, United States

and more 9 locations

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

First Posted Date
2008-06-30
Last Posted Date
2012-07-10
Lead Sponsor
Pfizer
Target Recruit Count
108
Registration Number
NCT00707239
Locations
🇨🇳

Pfizer Investigational Site, Taipei, Taiwan

Tigecycline for Treatment of Rapidly Growing Mycobacteria

First Posted Date
2008-01-25
Last Posted Date
2017-05-23
Lead Sponsor
The University of Texas Health Science Center at Tyler
Target Recruit Count
8
Registration Number
NCT00600600
Locations
🇺🇸

The University of Texas Health Science Center at Tyler, Tyler, Texas, United States

Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects

Phase 3
Completed
Conditions
Community-Acquired Infections
First Posted Date
2007-12-17
Last Posted Date
2011-06-03
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
9
Registration Number
NCT00575094

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI

Phase 4
Completed
Conditions
Abdominal Abscess
First Posted Date
2007-06-20
Last Posted Date
2009-07-07
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
50
Registration Number
NCT00488306

A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting

Completed
Conditions
Infection
Interventions
Drug: tigecycline
First Posted Date
2007-06-20
Last Posted Date
2011-07-22
Lead Sponsor
Pfizer
Target Recruit Count
1028
Registration Number
NCT00488488

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI

Phase 4
Completed
Conditions
Skin Diseases, Infectious
First Posted Date
2007-06-20
Last Posted Date
2007-12-28
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
50
Registration Number
NCT00488761

Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection

Phase 4
Completed
Conditions
Staphylococcal Infections
Interventions
Drug: Tigecycline
First Posted Date
2007-01-09
Last Posted Date
2011-06-22
Lead Sponsor
CPL Associates
Target Recruit Count
10
Registration Number
NCT00419991
Locations
🇺🇸

CPL Associates Investigational Site, Cumberland, Maryland, United States

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

Phase 1
Completed
Conditions
Liver Cirrhosis, Biliary
Interventions
Drug: tigecycline
First Posted Date
2006-12-04
Last Posted Date
2011-04-04
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
8
Registration Number
NCT00406237
Locations
🇵🇷

Pfizer Investigational Site, Santurce, Puerto Rico

Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone

Phase 1
Completed
Conditions
Healthy Subjects
First Posted Date
2006-09-14
Last Posted Date
2009-07-10
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
36
Registration Number
NCT00376324
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy